{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:54:17Z","timestamp":1784210057998,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101007873"],"award-info":[{"award-number":["101007873"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The global burden of tuberculosis (TB) remains high, and treatment of both drug-susceptible and drug-resistant diseases is complex and prolonged. International clinical trial networks and public-private partnerships are beginning to deliver advances in TB treatment, and collaborative data-sharing efforts are being promoted to improve the transparency and scrutiny of the evidence used in formulating treatment guidelines and public health policies. Empirical studies have identified variability in the selection and reporting of clinical trial outcomes in historical and recent phase III trial reports and protocols in TB. This variability could affect the synthesis of evidence and interpretation by practitioners, regulators, and policymakers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A comprehensive list of outcomes used in phase III treatment trials of pulmonary TB in adults, grouped according to key domains, will be identified from systematic reviews of published trials and trial protocols. A systematic review of qualitative evidence will inform outcomes important to people diagnosed with TB. Consensus will be sought from an international panel of participants representing key stakeholder groups using a multi-stage Delphi process. The final COS identified from the Delphi survey will be ratified at an online consensus meeting and approved by the SSC. The process will be conducted according to the Core Outcome Set-STAndards for Development (COS-STAD) guidance and with the support of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A COS implemented in the TB trials community that reflects the outcomes most important to stakeholders would help ensure that important evidence is translated rapidly, clearly, and effectively into practice to maximise patient benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The study has been registered with the COMET database of core outcome sets (study 2195, registered October 2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09224-8","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:52:10Z","timestamp":1763466730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protocol for the development of a Core Outcome Set (COS) for reporting outcomes of clinical trials of anti-tuberculosis treatment in adults with pulmonary tuberculosis"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-000X","authenticated-orcid":false,"given":"Rebecca","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola L.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula R.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraint R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TB-COS Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanif","family":"Esmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Leinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Rucsineanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessina","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Tudor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Chakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"9224_CR1","unstructured":"ACTG. https:\/\/www.cdc.gov\/tb\/research\/tbtc.html. Accessed 20th May 2024."},{"key":"9224_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13063-018-2522-x","volume":"19","author":"LJ Bonnett","year":"2018","unstructured":"Bonnett LJ, Ken-Dror G, Davies GR. Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review. Trials. 2018;19:134. https:\/\/doi.org\/10.1186\/s13063-018-2522-x.","journal-title":"Trials"},{"key":"9224_CR3","unstructured":"CDC TB Trials Consortium. https:\/\/www.cdc.gov\/tb\/research\/tbtc.html. Accessed 20th May 2024."},{"key":"9224_CR4","unstructured":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20132017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821\u2013834."},{"key":"9224_CR5","unstructured":"COMET initiative UK, Delphi manager. https:\/\/www.comet-initiative.org\/delphimanager\/index.html. Accessed 20 May 2024."},{"key":"9224_CR6","unstructured":"COMET initiative UK, overview. https:\/\/ctrc.liv.ac.uk\/InDevelopment\/Websites\/COMET\/about\/overview. Accessed 20 May 2024."},{"key":"9224_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893\u2013902.","journal-title":"N Engl J Med"},{"key":"9224_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.12.020","volume":"96","author":"S Dodd","year":"2018","unstructured":"Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol. 2018;96:84\u201392.","journal-title":"J Clin Epidemiol"},{"key":"9224_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384:1705\u201318.","journal-title":"N Engl J Med"},{"key":"9224_CR10","doi-asserted-by":"crossref","unstructured":"Guglielmetti L, Khan U, Vel\u00e1squez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD; endTB Clinical Trial Team. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. N Engl J Med. 2025;392(5):468\u2013482.","DOI":"10.1056\/NEJMoa2400327"},{"issue":"4","key":"9224_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. Grade guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395\u2013400.","journal-title":"J Clin Epidemiol"},{"key":"9224_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s13063-021-05388-1","volume":"22","author":"NK Hills","year":"2021","unstructured":"Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials. 2021;22:515. https:\/\/doi.org\/10.1186\/s13063-021-05388-1.","journal-title":"Trials"},{"key":"9224_CR13","unstructured":"Hills NK, Phillips P, Weir I. The specification of estimands in pulmonary TB treatment clinical trials: a proposal for improving standardization of endpoints and handling of intercurrent events utilizing the ICH E9 (R1) Addendum Framework 2021 (unpublished)."},{"key":"9224_CR14","doi-asserted-by":"crossref","unstructured":"Hoppe LE. Developing core outcome sets for clinical research and guideline development \u2013 qualitative systematic reviews to increase the volume, depth and diversity of patient perspectives included. Tuberculosis: a case study (MPhil Thesis). 2016. Available at: https:\/\/www.research.manchester.ac.uk\/portal\/files\/54586722\/FULL_TEXT.PDF.","DOI":"10.1186\/1745-6215-16-S1-O3"},{"key":"9224_CR15","first-page":"484","volume":"11","author":"S Khan","year":"2017","unstructured":"Khan S, Tangiisuran B, Imtiaz A, Zainal H. Health status and quality of life in tuberculosis: systematic review of study design, instruments, measuring properties and outcomes. Health Serv J. 2017;11:484\u201394.","journal-title":"Health Serv J"},{"key":"9224_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002447","volume":"14","author":"JJ Kirkham","year":"2017","unstructured":"Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core outcome set-STAndards for development: the COS-STAD recommendations. PLoS Med. 2017;14:e1002447.","journal-title":"PLoS Med"},{"key":"9224_CR17","doi-asserted-by":"crossref","unstructured":"Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Tunis S, Williamson PR; COS-STAP Group. Core outcome Set-STAndardised protocol items: the COS-STAP statement. Trials. 2019; 20:116.","DOI":"10.1186\/s13063-019-3230-x"},{"key":"9224_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","volume":"19","author":"GM Knight","year":"2019","unstructured":"Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19:903\u201312.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"9224_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002915","volume":"16","author":"C Lienhardt","year":"2019","unstructured":"Lienhardt C, Vernon A, Cavaleri M, Nabiar S, Nahid P. Development of new TB regimens: harmonizing trial design, product registration requirements, and public health guidance. PLoS Med. 2019;16(9):e1002915.","journal-title":"PLoS Med"},{"key":"9224_CR20","doi-asserted-by":"publisher","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","volume":"58","author":"NN Linh","year":"2021","unstructured":"Linh NN, Viney K, Gegia M, Falzon D, Glaziou P, Floyd K, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021;58:2100804.","journal-title":"Eur Respir J"},{"key":"9224_CR21","unstructured":"PanACEA. panacea-tb.net. Accessed 20th May 2024."},{"key":"9224_CR22","unstructured":"PAN-TB. https:\/\/www.pan-tb.org\/. Accessed 20th May 2024."},{"key":"9224_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0597-3","volume":"14","author":"PP Phillips","year":"2016","unstructured":"Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, et al. A new trial design to accelerate tuberculosis drug development: the phase IIC selection trial with extended post-treatment follow-up (STEP). BMC Med. 2016;14:51. https:\/\/doi.org\/10.1186\/s12916-016-0597-3.","journal-title":"BMC Med"},{"key":"9224_CR24","unstructured":"Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. 2016.\u00a0https:\/\/amr-review.org\/. Accessed 20th May 2024."},{"key":"9224_CR25","unstructured":"TB Alliance. https:\/\/www.tballiance.org\/. Accessed 20th May 2024."},{"key":"9224_CR26","unstructured":"UNITE4TB. https:\/\/www.unite4tb.org\/. Accessed 20th May 2024."},{"key":"9224_CR27","unstructured":"WHO. Global tuberculosis report 2024 global. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1. Accessed July 2025."},{"key":"9224_CR28","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis \u2013 rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376221\/9789240089488-eng.pdf?sequence=1. Accessed 08th\u00a0July 2024."},{"key":"9224_CR29","unstructured":"WHO. WHO consolidated guidelines on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/iris.who.int\/bitstream\/handle\/10665\/380799\/9789240107243-eng.pdf?sequence=1 Accessed July 2025."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09224-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09224-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:52:19Z","timestamp":1763466739000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09224-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9224"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09224-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval has been granted by the Institute of Population Health Research Ethics Committee (ref 12253). Written informed consent is a requirement for participant registration. The results of the Core Outcome Set (COS) process and recommendations will be shared with participants and stakeholder groups, including prominent clinical trial sponsors and networks, published in a peer-reviewed scientific manuscript, and disseminated at relevant international research meetings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. All steering committee members and participants will be asked to declare any relevant conflicts of interest before participating in the process. No conflicts of interest have been made by members of the study steering committee that precludes further participation in the process.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"521"}}